Meeting
2023 ASCO Annual Meeting
A phase II study of olaparib and durvalumab in patients with IDH-mutated cholangiocarcinoma.
Authors
Erica S. Tsang
Princess Margaret Cancer Centre, Toronto, ON, Canada
Erica S. Tsang , Grainne M. O'Kane , Jennifer J. Knox , Eric X Chen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03991832
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4099)
DOI
10.1200/JCO.2023.41.16_suppl.4099
Abstract #
4099
Poster Bd #
420
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II biomarker-oriented study to evaluate paclitaxel, olaparib, and durvalumab combination in patients with advanced gastric cancer.
First Author: Tae-Yong Kim
Poster
2020 ASCO Virtual Scientific Program
Phase II study of pembrolizumab plus olaparib in the treatment of patients with advanced cholangiocarcinoma.
First Author: Aiwu Ruth He
Poster
2019 ASCO Annual Meeting
Dora: A randomized phase II multicenter maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum responsive advanced triple-negative breast cancer (aTNBC).
First Author: Sarah Sammons
Poster
2019 Gastrointestinal Cancers Symposium
An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in patients with relapsed gastric cancer.
First Author: Yung-Jue Bang